厚壁黄斑病变消退与使用前蛋白转化酶枯草溶菌素9抑制剂之间的时间关联：一例报告
A Temporal Association between Regression of Pachydrusen and Use of Proprotein Convertase Subtilisin Kexin 9 Inhibitor: A Case Report.
作者信息
Chantarasorn Yodpong, Funilkul Kriengsak
机构信息
Department of Ophthalmology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
Cardiology Unit, Department of Internal Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
出版信息
Case Rep Ophthalmol. 2024 Aug 8;15(1):614-620. doi: 10.1159/000540014. eCollection 2024 Jan-Dec.
INTRODUCTION
We aim to report the clinical course of a patient with pachychoroidopathy who experienced regression of subfoveal drusen during cholesterol treatment using PCSK9 inhibitors.
CASE PRESENTATION
A 62-year-old woman who was visually asymptomatic complained of recent visual loss in the left eye (OS). She was diagnosed with foveal pachydrusen (OS) that had remained stable for 10 years. Three months after starting cholesterol treatment with a PCSK9 inhibitor, the latest class of lipid-lowering medication, her vision improved in parallel with gradual regression of material deposited beneath the retinal pigment epithelium (RPE). Recurrence of drusen was observed after discontinuing the drug.
CONCLUSIONS
Use of PCSK9 inhibitors may improve the retina's lipid homeostasis by increasing the number of RPE-LDL receptors and partly contribute to the improvement of ocular phenotypes associated with dysfunctional RPE in pachychoroidopathy.
引言
我们旨在报告一名患有厚脉络膜病变的患者在使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂进行胆固醇治疗期间，其黄斑下玻璃膜疣消退的临床过程。
病例介绍
一名62岁视力无症状的女性抱怨近期左眼视力下降。她被诊断为黄斑部厚玻璃膜疣（左眼），且已稳定存在10年。在用最新一类降脂药物PCSK9抑制剂开始胆固醇治疗三个月后，她的视力随着视网膜色素上皮（RPE）下沉积物质的逐渐消退而改善。停药后观察到玻璃膜疣复发。
结论
使用PCSK9抑制剂可能通过增加RPE-LDL受体数量来改善视网膜脂质稳态，并部分有助于改善厚脉络膜病变中与功能失调的RPE相关的眼部表型。
Zotero 插件